{
    "Clinical Trial ID": "NCT00696072",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Dasatinib Plus Letrozole",
        "  Dasatinib + Letrozole: Tablets, Oral, once daily, up to 2 years",
        "  Dasatinib 100 mg + Letrozole 2.5 mg",
        "  Patients on letrozole plus dasatinib received both drugs until progressive disease (PD) or intolerable toxicity. If the intolerable toxicity was determined to be related to dasatinib, dasatinib was discontinued and the patient continued on single-agent letrozole. Although drugs were taken daily, cycle length was 28-days",
        "INTERVENTION 2: ",
        "  Letrozole",
        "  Letrozole: Tablets, Oral, 2.5 mg, once daily, up to 2 years",
        "  Patients on letrozole who developed progressive disease continued letrozole, and dasatinib was added to their treatment regimen. Although drugs were taken daily, cycle length was 28-days"
    ],
    "Eligibility": [
        "For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.",
        "Inclusion Criteria:",
        "  Has histologic or cytologic diagnosis of breast cancer; evidence of unresectable locally recurrent or metastatic disease",
        "  Has measurable or evaluable-only disease",
        "  Is female, 18 yrs of age, post menopausal or surgically sterile",
        "  HER2 negative, HR+, ER+ and/or PgR+ breast cancer",
        "  0-1 prior chemotherapy regimen for metastatic disease.",
        "  Prior adjuvant or neoadjuvant chemotherapy completed at least 1 month prior",
        "  Prior tamoxifen therapy is allowed",
        "  No AI therapy for >1 year without recurrence",
        "Exclusion Criteria:",
        "  Pregnant or breast feeding",
        "  Prior hormonal therapy for metastatic or locally recurrent disease",
        "  >1 chemotherapy regimen for metastatic disease",
        "  Pleural or pericardial effusion",
        "  Serious cardiac condition"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population",
        "  CBR=participants with complete response (CR) + participants with partial response (PR) + participants with stable disease (SD) for a length of time greater than, equal to 6 months. CR= Disappearance of all target lesions. No new lesions. PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started. Physical examination,radiological assessment, and bone scans (if applicable) were used to assess outcome.",
        "  Time frame: First dose of study drug to last dose plus 7 days, up to study completion (approximately 6 years)",
        "Results 1: ",
        "  Arm/Group Title: Dasatinib Plus Letrozole",
        "  Arm/Group Description: Dasatinib + Letrozole: Tablets, Oral, once daily, up to 2 years",
        "  Dasatinib 100 mg + Letrozole 2.5 mg",
        "  Patients on letrozole plus dasatinib received both drugs until progressive disease (PD) or intolerable toxicity. If the intolerable toxicity was determined to be related to dasatinib, dasatinib was discontinued and the patient continued on single-agent letrozole. Although drugs were taken daily, cycle length was 28-days",
        "  Overall Number of Participants Analyzed: 56",
        "  Measure Type: Number",
        "  Unit of Measure: participants  CBR (CR+PR+SD): 40",
        "  CBR, DFI <= 2 Years: 20",
        "CBR, DFI > 2 Years: 20",
        "Results 2: ",
        "  Arm/Group Title: Letrozole",
        "  Arm/Group Description: Letrozole: Tablets, Oral, 2.5 mg, once daily, up to 2 years",
        "  Patients on letrozole who developed progressive disease continued letrozole, and dasatinib was added to their treatment regimen. Although drugs were taken daily, cycle length was 28-days",
        "  Overall Number of Participants Analyzed: 61",
        "  Measure Type: Number",
        "  Unit of Measure: participants  CBR (CR+PR+SD): 40",
        "  CBR, DFI <= 2 Years: 20",
        "CBR, DFI > 2 Years: 20"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 14/57 (24.56%)",
        "  Anemia * 0/57 (0.00%)",
        "  CVA * 2/57 (3.51%)",
        "  Cardiac Insufficiency * 0/57 (0.00%)",
        "  Congestive Heart Failure * 0/57 (0.00%)",
        "  Coronary Insufficiency * 1/57 (1.75%)",
        "  Effusion Pericardial * 0/57 (0.00%)",
        "  Cholelithiasis * 1/57 (1.75%)",
        "  Colitis * 0/57 (0.00%)",
        "  Dehydration * 1/57 (1.75%)",
        "  Diverticulitis * 0/57 (0.00%)",
        "  Nausea * 2/57 (3.51%)",
        "Adverse Events 2:",
        "  Total: 2/63 (3.17%)",
        "  Anemia * 1/63 (1.59%)",
        "  CVA * 0/63 (0.00%)",
        "  Cardiac Insufficiency * 1/63 (1.59%)",
        "  Congestive Heart Failure * 1/63 (1.59%)",
        "  Coronary Insufficiency * 0/63 (0.00%)",
        "  Effusion Pericardial * 1/63 (1.59%)",
        "  Cholelithiasis * 0/63 (0.00%)",
        "  Colitis * 1/63 (1.59%)",
        "  Dehydration * 1/63 (1.59%)",
        "  Diverticulitis * 1/63 (1.59%)",
        "  Nausea * 0/63 (0.00%)"
    ]
}